Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Table 1 Clinical characteristics of patients ( n = 120) in whom local-regional progression-free survival was assessed

Variable	<63 Gy	≥63 Gy	χ ²	p
Gender
Male	33	53	2.387	0.122
Female	8	26	2.387	0.122
Age (years)
<65	27	55	0.177	0.674
≥65	14	24	0.177	0.674
Pathological type
Squamous	17	23	5.268	0.072
Adenocarcinoma	18	51
Other types	6	5
T stage
T1	3	7	2.371	0.499
T2	17	23
T3	6	10
T4	15	39
N stage
N0	3	5	2.631^#	0.444
N1	2	10
N2	14	31
N3	22	33
GTV (cm³)	23.64 ~ 892.00 (204.91)	16.55 ~ 617.50 (160.51)	1.108*	0.171
Chemotherapy
2-3 cycles	23	23	8.314	0.004
4-5 cycles	18	56	8.314	0.004
Range (median)	2-4 (3)	2-5 (4)
Organ metastases
Single organ	27	54	0.077	0.781
Multi-organ	14	25	0.077	0.781
Treatment response of primary tumor
CR	1	10	3.961	0.138
PR	32	59
NC	8	10

Note: *Student t-test; GTV from a minimum–maximal value (median); ^#Fisher’s exact test.

ISSN: 1471-2407